Comparison of effects of low dose of spironolactone and a thiazide diuretic in patients with hypertension treated with an angiotensin-converting enzyme inhibitor or an angiotensin type 1 receptor blocker

Clinical and Experimental Hypertension

Volumn 31, Issue 8, 2009, Pages 648-656

  Yutaka, Miyashita ^a,b   Mifune, Mizuo ^c   Kubota, Eiji ^b   Itoh, Hiroshi ^d   Saito, Ikuo ^d  

^a Miyashita Naika Clinic   (Japan)

^b SHIZUOKA RED CROSS HOSPITAL   (Japan)

^c 2 24 18 Higashikoiwa   (Japan)

^d KEIO UNIVERSITY   (Japan)

Author keywords

Hypertension; Spironolactone; Thiazide diuretics

Indexed keywords

ALBUMIN; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; LIPID; POTASSIUM; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; TRICHLORMETHIAZIDE; URIC ACID;

AGED; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; POTASSIUM BLOOD LEVEL; URINARY EXCRETION;

AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; DIURETICS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; MIDDLE AGED; OUTPATIENTS; PROSPECTIVE STUDIES; SPIRONOLACTONE; TREATMENT OUTCOME; TRICHLORMETHIAZIDE;

EID: 72749097229     PISSN: 10641963     EISSN: 15256006     Source Type: Journal    
DOI: 10.3109/10641960903407017     Document Type: Article

References (20)

1. Chobanian AV, Bakris GL, Black HR, et al. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42(6):1206-1252.
2. Japanese Society of Hypertension. Guidelines for the management of hypertension (JSH 2004). Hypertens Res Aug 2006;29 suppl:S1-105.
3. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25(6):1105-1187. (Pubitemid 46924065)
4. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med 1999;341(10):709-717.
5. Gumieniak O, Williams GH. Mineralocorticoid receptor antagonists and hypertension: Is there a rationale? Curr Hypertens Rep 2004;6(4):279-287.
6. Ouzan J, Perault C, Lincoff AM, et al. The role of spironolactone in the treatment of patients with refractory hypertension. Am J Hypertens 2002;15(4 Pt 1):333-339.
7. Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 2003;16(11 Pt 1):925-930.
8. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007;28(12):1462-1536.
9. Rocha R, Funder JW. The pathophysiology of aldosterone in the cardiovascular system. Ann N Y Acad Sci 2002;970:89-100.
10. Sato A, Saruta T. Aldosterone breakthrough during angiotensin-converting enzyme inhibitor therapy. Am J Hypertens 2003;16(9 Pt 1):781-788.
11. Arima S. Aldosterone and the kidney: Rapid regulation of renal microcirculation. Steroids 2006;71(4):281-285.
12. Kasama S, Toyama T, Sumino H, et al. Additive effects of spironolactone and candesartan on cardiac sympathetic nerve activity and left ventricular remodeling in patients with congestive heart failure. J Nucl Med 2007;48(12):1993-2000. (Pubitemid 350232308)
13. Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: A meta-analysis. Lancet 20 2001;358(9290):1305-1315.
14. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the randomized aldactone evaluation study. N Engl J Med 2004;351(6):543-551.
15. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348(14):1309-1321.
16. Sato A, Hayashi K, Naruse M, et al. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 2003;41(1):64-68.
17. Ogawa S, Takeuchi K, Mori T, et al. Spironolactone further reduces urinary albumin excretion and plasma B-type natriuretic peptide levels in hypertensive type II diabetes treated with angiotensin-converting enzyme inhibitor. Clin Exp Pharmacol Physiol 2006;33(5-6):477-479.
18. Sato A, Suzuki Y, Saruta T. Effects of spironolactone and angiotensin-converting enzyme inhibitor on left ventricular hypertrophy in patients with essential hypertension. Hypertens Res 1999;22(1):17-22.
19. Chapman N, Dobson J, Wilson S, et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007;49(4):839-845.
20. Williams B, Poulter NR, Brown MJ, et al. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): Summary. BMJ 2004;328(7440):634-640. (Pubitemid 38340037)